Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ProMIS Neurosciences, Inc. before investing.

In this article, we go over a few key elements for understanding ProMIS Neurosciences, Inc.’s stock price such as:

• ProMIS Neurosciences, Inc.’s current stock price and volume
• Why ProMIS Neurosciences, Inc.’s stock price changed recently
• Upgrades and downgrades for PMN from analysts
• PMN’s stock price momentum as measured by its relative strength

About ProMIS Neurosciences, Inc. (PMN)

Before we jump into ProMIS Neurosciences, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington’s disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

Want to learn more about ProMIS Neurosciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about ProMIS Neurosciences, Inc..

ProMIS Neurosciences, Inc.’s Stock Price as of Market Close

As of May 21, 2026, 1:29 PM, CST, ProMIS Neurosciences, Inc.’s stock price was $10.920.

ProMIS Neurosciences, Inc. is up 3.02% from its previous closing price of $10.600.

During the last market session, ProMIS Neurosciences, Inc.’s stock traded between $10.500 and $10.920. Currently, there are approximately 6.53 million shares outstanding for ProMIS Neurosciences, Inc..

ProMIS Neurosciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

ProMIS Neurosciences, Inc. Stock Price History

ProMIS Neurosciences, Inc.’s (PMN) price is currently down 1.09% so far this month.

During the month of May, ProMIS Neurosciences, Inc.’s stock price has reached a high of $11.500 and a low of $9.310.

Over the last year, ProMIS Neurosciences, Inc. has hit prices as high as $39.750 and as low as $6.270. Year to date, ProMIS Neurosciences, Inc.’s stock is up 60%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused ProMIS Neurosciences, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 20, 2026, there were analysts who downgraded ProMIS Neurosciences, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate ProMIS Neurosciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on ProMIS Neurosciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about ProMIS Neurosciences, Inc. (PMN) by visiting AAII Stock Evaluator.

Relative Price Strength of ProMIS Neurosciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 20, 2026, ProMIS Neurosciences, Inc. has a weighted four-quarter relative price strength of -9.59%, which translates to a Momentum Score of 29 and is considered to be Weak.

Want to learn more about how ProMIS Neurosciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

ProMIS Neurosciences, Inc. Stock Price: Bottom Line

As of May 21, 2026, ProMIS Neurosciences, Inc.’s stock price is $10.920, which is up 3.02% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like ProMIS Neurosciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.